Ivermectin in the prevention of covid-19

A Clinical Trial to Study the Efficacy of â??Ivermectinâ?? in the prevention of Covid-19. .A Single Arm Study. â??

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/06/026232

Enrollment

Registered

2020-06-29

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Ivermectin: Single oral dose of 200 mcg of ivermectin per kg of body weight. Control Intervention1: Not applicable: Not applicable

Eligibility

Inclusion criteria

Inclusion criteria: Subjects who are not suffering from active illness due to infection at the time of inclusion .

Exclusion criteria

Exclusion criteria: 1.Pregnant and lactating women. 2.Subjects suffering from active illness due to infection at the time of inclusion. 3.Subjects suffering from uncontrolled DM, HTN etc 4.Subjects who are known cases of immune-compromised or autoimmune condition such as HIV.

Design outcomes

Primary

Measure	Time frame
Episodes and severity of symptoms of respiratory tract infection (cold, sore throat, dry cough, breathlessness) in subjects who may get direct or indirect exposure to COVID 19 patients.Timepoint: From Baseline till the end of 15 days.	—

Secondary

Measure	Time frame
Requirement of treatment for symptoms developed, if any, during study period. Incidence of COVID 19 infection in study population. Analysis of adverse events, if anyTimepoint: From Baseline till the end of 15 days. From Baseline till the end of 15 days. From Baseline till the end of 15 days.	—

Countries

India

Contacts

Public ContactBKumar

DVFM

bkumar09460946@gmail.com9505637454

Outcome results